Exyte Empowers the Biopharmaceutical Industry

Stuttgart and Bergisch Gladbach, 29 July 2021. Exyte has successfully completed the construction of the first ExyCell® facility in China, the CliniMACS Cell Factory® of Miltenyi Biotec, a global provider of integrated solutions for Advanced Therapy Medical Products (ATMPs). The patented ExyCell technology was developed by Exyte as an end-to-end, integrated facility solution with standardized and modularized elements. These pre-configured and pre-fabricated modules enable fast-track construction thereby shortening time-to-market for new therapeutics and vaccines. The ExyCell facility is installed on the fourth floor of the ATLATL building located in the Zhangjiang High-Tech Park, and Miltenyi Biotec is now transferring production technology from Germany to China with regular operations for ATMP production is expected by autumn 2021. The facility will soon be open to visitors by appointment.

Through their cooperation, Exyte and Miltenyi Biotec have developed an innovative, sustainable, and cost-effective facility for cell therapy manufacturing. This facility combines the CliniMACS Cell Factory manufacturing platform with the pre-fabricated ExyCell module enabling a fast deployment of small, medium, and large scale cell manufacturing facilities based on a flexible cell therapy manufacturing module. Endusers can purchase a personalized version of this pre-engineered and pre-fabricated manufacturing module ready to host their CliniMACSCell Factory for ATMPs. 

Chris Miller, President Global Business Unit Biopharma and Life Sciences at Exyte stated: “The completion of the first ExyCell facility with our partner Miltenyi Biotec marks an important milestone. We consider ExyCell to be a transformational development of our “next generation” of award winning modular concepts.” Exyte has developed and implemented several other modular facilities including the renowned Catapult Development and Manufacturing Centre for cell and gene therapy in Stevenage, UK, several modular biotech facilities in China, and a large modular biomanufacturing facility for upstream and downstream processing in Lithuania. All these plants have been designed and constructed, shipped, and installed for operational readiness. 

Dr. Boris Stoffel, Member of the Management Board of Miltenyi Biotec, emphasized the importance of this partnership: “As a company, we want to enable our customers in their efforts to make innovative cell and gene therapies available to patients worldwide. We believe that combining the proven CliniMACS Cell Factory manufacturing platform with the pre-fabricated ExyCell module will help fast-tracking new therapies to the benefit of global healthcare.”  

The effective combination of the CliniMACS Cell Factory ballroom concept built into the ExyCell module allows the flexibility to build, scale-up, expand, or repurpose a facility with minimal impact to ongoing production operations. The ExyCell platform can either be purchased in its standard version or adapted to specific needs of production capacity, cleanroom size, control systems, and finishing options. Exyte can build and qualify a turn-key ExyCell facility in a matter of months. The ExyCell facility sizes start from 75 m2 for a fully equipped and operational turnkey facility hosting a CliniMACS Cell Factory with one to twelve CliniMACS Prodigy® units, scaling up to several thousand square meters to accomodate several hundred units. The ExyCell facility can be either realized in an existing building or built in a greenfield setting and presents clients with the opportunity for a significant reduction in construction timelines and overall energy use. The design is adaptable to any process layout and meets the requirements for current Good Manufacturing Practice (cGMP). 

Innovations in process technology, adaptable plant design, combined with the integration of physical and virtual supply chains allow biopharmaceutical manufacturers to remain competitive in a dynamic market. Biopharmaceutical manufacturers will benefit from the end-to-end sustainable solutions, which can be deployed globally, are cost predictable, provide speed to market, and flexibility for facility re-purposing. This reflects the characteristics of a drug lifecycle, mitigates associated risks, and effectively protects the CAPEX (capital expenditure) and OPEX (operational expenditure).

Contact Person

Adriana Williams
VP Corporate Communications & Investor Relations

Phone: +49 711 8804-1489